Literature DB >> 29522809

Onset and Evolution of Clinically Apparent Myasthenia Gravis After Resection of Non-myasthenic Thymomas.

Tommaso Claudio Mineo1, Alessandro Tamburrini2, Orazio Schillaci3, Vincenzo Ambrogi4.   

Abstract

Patients with thymoma and without clinical or electromyographical myasthenic signs may occasionally develop myasthenia several years after thymectomy. Hereby, we investigated the predictors and the evolution of this peculiar disease. We performed a retrospective analysis in 104 consecutive patients who underwent thymectomy between 1987 and 2013 for thymoma without clinical or electromyographic signs of myasthenia gravis. Predictors of post-thymectomy onset of myasthenia gravis were investigated with univariate time-to-disease analysis. Evolution of myasthenia was analyzed with time-to-regression analysis. Eight patients developed late myasthenia gravis after a median period of 33 months from thymectomy. No significant correlation was found for age, gender, Masaoka's stage, and World Health Organization histology. Only high preoperative serum acetylcholine-receptor antibodies titer (>0.3 nmol/L) was significantly associated with post-thymectomy myasthenia gravis at univariate time-to-disease (P = 0.003) analysis. Positron emission tomography was always performed in high-titer patients, and increased metabolic activity was detected in 4 of these patients. Surgical treatment through redo-sternotomy or video-assisted thoracoscopy was performed in these last cases with a remission in all patients after 12, 24, 32 and 48 months, respectively. No patient under medical treatment has yet developed a complete remission. In our study the presence of preoperative high-level serum acetylcholine receptor antibodies was the only factor significantly associated with the development of post-thymectomy myasthenia gravis. The persistence of residual islet of ectopic thymic tissue was one of the causes of the onset of myasthenia and its surgical removal was successful.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acetylcholine receptor antibodies; myasthenia gravis; thymectomy; thymoma

Mesh:

Substances:

Year:  2018        PMID: 29522809     DOI: 10.1053/j.semtcvs.2018.02.027

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  4 in total

1.  Relationship between anti-acetylcholine receptor antibodies and the development of post-thymectomy myasthenia gravis in patients with thymoma: a single-center experience.

Authors:  Yusuke Nabe; Teppei Hashimoto; Kanji Tanaka; Yasuhiro Fujita; Katsuma Yoshimatsu; Yukiko Nemoto; Rintaro Oyama; Hiroki Matsumiya; Masataka Mori; Masatoshi Kanayama; Akihiro Taira; Shinji Shinohara; Taiji Kuwata; Masaru Takenaka; Yuko Tashima; Koji Kuroda; Fumihiro Tanaka
Journal:  Gland Surg       Date:  2021-08

2.  Surgical outcomes of 215 patients with thymic epithelial tumors: A single-center experience.

Authors:  Wenxin Tian; Yaoguang Sun; Qingjun Wu; Peng Jiao; Chao Ma; Hanbo Yu; Chuan Huang; Hongfeng Tong
Journal:  Thorac Cancer       Date:  2020-05-08       Impact factor: 3.500

3.  Refractory post-thymectomy myasthenia gravis with onset at MGFA stage V: a case report.

Authors:  Rui-Qin Zhou; Lin-Jun Li; Qing-Chen Wu
Journal:  J Cardiothorac Surg       Date:  2022-05-12       Impact factor: 1.522

4.  Surgical effect and prognostic factors of myasthenia gravis with thymomas.

Authors:  Wenxin Tian; Xiao Li; Hongfeng Tong; Wenhan Weng; Fan Yang; Guanchao Jiang; Jun Wang
Journal:  Thorac Cancer       Date:  2020-03-19       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.